Clik here to view.
Biotech Omthera Pharmaceuticals sets terms for $75 million IPO
Omthera Pharmaceuticals, which is developing therapies for abnormalities in blood lipids, announced terms for its IPO on Monday. The Princeton, NJ-based company plans to raise $75 million by
View ArticleClik here to view.
Four IPOs set terms as April's US IPO calendar quickly builds
Three new deals filed terms Monday morning, as homebuilder Taylor Morrison ( TMHC ) and biotechs Chimerix ( CMRX ) and Omthera Pharmaceuticals ( OMTH ) hit the calendar, bringing the
View ArticleClik here to view.
7 US IPOs planned for the week of Apr 8
The following IPOs are expected to price this week : Chimerix ( CMRX ), which is developing a potent antiviral drug for use in stem cell transplants, plans to raise $85 million by
View ArticleClik here to view.
Omthera Pharmaceuticals prices upsized IPO below the range at $8
Omthera Pharmaceuticals, which has developed a prescription fish oil capsule that reduces triglyceride levels, raised $64 million by offering 8.0 million shares at $8, well below the range of
View ArticleClik here to view.
Chimerix stock soars as two biotechs debut Thursday
Two biotechs, Chimerix ( CMRX ) and Omthera Pharmaceuticals ( OMTH ), debuted on Thursday, bringing the total to five deals that have priced in April. Chimerix finished the
View ArticleClik here to view.
AstraZeneca to Buy Omthera Pharma - Analyst Blog
Recently, AstraZeneca ( AZN ) entered into a definitive agreement to purchase US based specialty pharmaceutical company, Omthera Pharmaceuticals ( OMTH ) for approximately $323 million
View ArticleClik here to view.
US IPO Recap: May ends with 30 pricings, two billion-dollar deals set for June
Epizyme ( EPZM ) and Kamada ( KMDA ), the only IPOs to be completed in a relatively quiet week, pushed the IPO market into new post-recession territory on Friday. The two deals were the
View ArticleClik here to view.
AstraZeneca to Buy Pearl Therapeutics - Analyst Blog
Recently, AstraZeneca ( AZN ) entered into a definitive agreement to purchase US-based privately-held company Pearl Therapeutics. The deal will add late-stage chronic obstructive pulmonary
View ArticleClik here to view.
AstraZeneca and NGM Collaborate - Analyst Blog
AstraZeneca ( AZN ) recently announced that MedImmune (the biologics research and development arm of AstraZeneca) has entered into an agreement with privately-held US-based company, NGM
View ArticleClik here to view.
Omthera Seeks FDA Approval for Epanova - Analyst Blog
Omthera Pharmaceuticals, Inc. ( OMTH ) recently submitted a new drug application (NDA) for its cholesterol management candidate, Epanova. Omthera is seeking US Food and Drug Administration (FDA)
View Article
